{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:45:50Z","timestamp":1762004750544},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Healt","award":["836011009"],"award-info":[{"award-number":["836011009"]}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.ymgme.2015.11.014","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T07:50:30Z","timestamp":1448956230000},"page":"194-198","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort"],"prefix":"10.1016","volume":"117","author":[{"given":"Maarten","family":"Arends","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabor E.","family":"Linthorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla E.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke","family":"Biegstraaten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2015.11.014_bb0005","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry's disease: alpha-galactosidase deficiency","volume":"167","author":"Kint","year":"1970","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0010","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0015","series-title":"OMMBID \u2014 The Online Metabolic and Molecular Bases of Inherited Diseases","article-title":"\u0391-galactosidase a deficiency: Fabry disease","author":"Desnick","year":"2013"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1750-1172-8-47","article-title":"Long term enzyme replacement therapy for fabry disease: effectiveness on kidney, heart and brain","volume":"8","author":"Rombach","year":"2013","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0025","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0030","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54months of agalsidase beta therapy in patients with Fabry disease","volume":"18","author":"Germain","year":"2007","journal-title":"Journal of the American Society of Nephrology JASN"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0035","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfs526","article-title":"Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice Nephrology, dialysis, transplantation","volume":"28","author":"Terryn","year":"2013","journal-title":"Official Publication of the European Dialysis and Transplant Association \u2014 European Renal Association"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0045","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0050","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/joim.12089","article-title":"Fabry disease: is there a role for enzyme replacement therapy?","volume":"274","author":"Mehta","year":"2013","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0055","doi-asserted-by":"crossref","DOI":"10.1007\/s10545-014-9677-8","article-title":"Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis Effectiveness of ERT in different disease stages","author":"Rombach","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0060","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijcard.2014.09.001","article-title":"Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance","volume":"177","author":"Smid","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0070","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography\u2013tandem mass spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0080","series-title":"Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","first-page":"1","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, KDIGO 2012","year":"2013"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0085","doi-asserted-by":"crossref","first-page":"175S","DOI":"10.1093\/ajh\/5.6.175S","article-title":"Left ventricular mass as a measure of preclinical hypertensive disease","volume":"5","author":"Devereux","year":"1992","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0090","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","article-title":"A revised home treatment algorithm for Fabry disease: influence of antibody formation","volume":"108","author":"Smid","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A \u2014 replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0100","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0105","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000369293","article-title":"Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease","volume":"38","author":"Fellgiebel","year":"2014","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0110","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","article-title":"Central nervous system involvement in Anderson\u2013Fabry disease: a clinical and MRI retrospective study","volume":"79","author":"Buechner","year":"2008","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0115","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/jmg.38.11.750","article-title":"Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2014.01.014","article-title":"Outcomes of patients treated through the Canadian Fabry Disease Initiative","author":"Sirrs","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome \u2014 an expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0130","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ymgme.2012.08.013","article-title":"Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature","volume":"107","author":"Jurecka","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0135","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2013.08.019","article-title":"Effect of rapid cessation of enzyme replacement therapy: a report of 5 more cases","volume":"111","author":"Jurecka","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0140","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/00125817-200211000-00005","article-title":"2nd, Cessation of enzyme replacement therapy in Gaucher disease Genetics in medicine","volume":"4","author":"Grinzaid","year":"2002","journal-title":"Official Journal of the American College of Medical Genetics"},{"key":"10.1016\/j.ymgme.2015.11.014_bb0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bcmd.2010.05.001","article-title":"Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supply","volume":"46","author":"Zimran","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.ymgme.2015.11.014_bb0150","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bcmd.2010.05.002","article-title":"Enzyme replacement therapy \u201cdrug holiday\u201d: results from an unexpected shortage of an orphan drug supply in Australia","volume":"46","author":"Goldblatt","year":"2011","journal-title":"Blood Cells Mol. Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719215300846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T08:26:28Z","timestamp":1537172788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719215300846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1096719215300846"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.11.014","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discontinuation of enzyme replacement therapy in Fabry disease in the Dutch cohort","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2015.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}